Marksans Pharma on Tuesday said that UK MHRA has granted marketing authorisation to its wholly-owned subsidiary, Relonchem Ltd, UK, for loratadine 5mg/5ml oral solution. The product will be manufactured in its UK facility. Loratadine oral solution is indicated for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria in adults and children. Shares of Marksans Pharma declined 2.2 per cent at ₹24.35 on the NSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.